What are the specific functions and efficacy of acotinib/kancochi capsules?

Acalabrutinib (Acalabrutinib) is a new generation of BTK inhibitors that has received widespread attention because of its high selectivity. It achieves anti-tumor effects by targeting and inhibiting Bruton's tyrosine kinase (BTK) in the B cell receptor signaling pathway, blocking the proliferation and survival of malignant B cells. Compared with the first-generation representative drug ibrutinib, acotinib is more targeted in molecular design and can significantly reduce adverse reactions caused by non-specific inhibition, so it is often better tolerated in clinical applications.

In terms of indications, acotinib is widely used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and relapsed or refractory mantle cell lymphoma (MCL). These diseases are all malignant hematological tumors derived from B cells. In the past, treatment options were limited, and traditional chemotherapy often caused major side effects. The emergence of acotinib provides patients with a new oral targeted treatment option. Clinical observations have found that acotinib has positive significance in improving progression-free survival time, and also shows good efficacy in some patients with high-risk mutations.

In addition to its core anti-tumor efficacy, another major advantage of acotinib is the feasibility of long-term use. Due to its stronger selectivity, it avoids excessive inhibition of non-targets such as the TEC family, thereby reducing the incidence of adverse events such as bleeding and arrhythmia. This means that patients can maintain better tolerance during long-term treatment, helping to improve compliance and quality of life. The safety profile of acotinib is particularly valuable for patients with chronic hematological diseases who require long-term maintenance therapy.

As more real-world data accumulates, the application prospects of acotinib continue to expand. Some studies are exploring its combination therapy with other new immune drugs or targeted drugs in order to extend the duration of efficacy and overcome the problem of drug resistance.

Reference materials:https://www.calquence.com/